Condition
Breast Cancer (Triple Negative Breast Cancer (TNBC))
Total Trials
4
Recruiting
1
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (1)
P 2 (1)
Trial Status
Not Yet Recruiting1
Completed1
Recruiting1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07555210Not ApplicableRecruitingPrimary
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
NCT07498400Not ApplicableActive Not RecruitingPrimary
Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer
NCT07487519Phase 2Not Yet RecruitingPrimary
Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.
NCT02316457Phase 1CompletedPrimary
RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID
Showing all 4 trials